Last reviewed · How we verify
Lexiscan
At a glance
| Generic name | Lexiscan |
|---|---|
| Also known as | Regadenoson |
| Sponsor | Medical University of South Carolina |
| Target | Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Myocardial Perfusion Imaging Adjunct
Common side effects
- Dyspnea
- Headache
- Chest pain
- Dizziness
- Palpitations
- Flushing
- Nausea
- Wheezing
- Tachycardia
- Arrhythmia
Serious adverse events
- Myocardial Ischemia
- Sinoatrial and Atrioventricular Nodal Block
- Atrial Fibrillation/Atrial Flutter
- Anaphylaxis
- Hypotension
- Hypertension
- Bronchoconstriction
- Seizure
- Cerebrovascular Accident (Stroke)
Key clinical trials
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System (NA)
- Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
- Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients (PHASE1, PHASE2)
- Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |